Disease · MONDO_0003539

T-cell adult acute lymphocytic leukemia

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. T-cell adult acute lymphocytic leukemia. Diseases, record MONDO_0003539. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0003539

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: T-cell adult acute lymphocytic leukemia; Open Targets
Open Targets ID: MONDO_0003539; Open Targets
Other names: T Acute Lymphoblastic Leukemia, T cell adult ALL, T cell adult acute lymphoblastic leukaemia, T cell adult acute lymphoblastic leukemia, T cell adult acute lymphocytic leukaemia, acute Adult T-cell Leukemia-lymphoma, adult T acute lymphoblastic leukaemia, adult T acute lymphoblastic leukemia, adult T-cell acute lymphoblastic leukaemia, adult T-cell acute lymphoblastic leukemia, adult acute lymphoblastic leukaemia of T cell, adult acute lymphoblastic leukemia of T cell, adult precursor T lymphoblastic leukaemia, adult precursor T lymphoblastic leukemia; Open Targets
Disease Ontology: DOID:5602; Disease Ontology
NCI Thesaurus: C9142; NCI Thesaurus
Highest stage of its drugs: Phase 3, for 9 of its 31 drugs, from ClinicalTrials.gov; Open Targets

Drugs31

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
CYTARABINE	CHEMBL803	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
ACLARUBICIN	CHEMBL502620	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
FILGRASTIM	CHEMBL1201567	Protein	Phase 3	ClinicalTrials.gov	1	1	0	Drugs and targets
IMATINIB MESYLATE	CHEMBL1642	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
LENOGRASTIM	CHEMBL2109128	Protein	Phase 3	ClinicalTrials.gov	1	1	0	Drugs and targets
OMACETAXINE MEPESUCCINATE	CHEMBL46286	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
PEGFILGRASTIM	CHEMBL1201568	Protein	Phase 3	ClinicalTrials.gov	1	1	0	Drugs and targets
RITUXIMAB	CHEMBL1201576	Antibody	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
VENETOCLAX	CHEMBL3137309	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
BLINATUMOMAB	CHEMBL1742992	Antibody	Phase 2/3	ClinicalTrials.gov	1	1	1	Drugs and targets

1 to 10 of 31

See all 31 drugs

Targets103

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
TOP2A	DNA topoisomerase 2-alpha	4	DNA topoisomerase II alpha inhibitor; DNA topoisomerase II inhibitor	Phase 2/3	https://conductscience.org/library/genes/7153	Drugs and targets
CSF3R	Granulocyte colony-stimulating factor receptor	3	Granulocyte colony stimulating factor receptor agonist	Phase 3	https://conductscience.org/library/genes/1441	Drugs and targets
ABL1	Bcr/Abl fusion protein	2	Bcr/Abl fusion protein inhibitor; Tyrosine-protein kinase ABL inhibitor	Phase 3	https://conductscience.org/library/genes/25	Drugs and targets
BCR	Bcr/Abl fusion protein	2	Bcr/Abl fusion protein inhibitor	Phase 3	https://conductscience.org/library/genes/613	Drugs and targets
CD38	ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1	2	Lymphocyte differentiation antigen CD38 inhibitor	Phase 2	https://conductscience.org/library/genes/952	Drugs and targets
KIT	Mast/stem cell growth factor receptor Kit	2	Stem cell growth factor receptor inhibitor	Phase 3	https://conductscience.org/library/genes/3815	Drugs and targets
NR3C1	Glucocorticoid receptor	2	Glucocorticoid receptor agonist	Phase 2/3	https://conductscience.org/library/genes/2908	Drugs and targets
PDGFRB	Platelet-derived growth factor receptor beta	2	Platelet-derived growth factor receptor beta inhibitor	Phase 3	https://conductscience.org/library/genes/5159	Drugs and targets
POLA1	DNA polymerase (alpha/delta/epsilon)	2	DNA polymerase (alpha/delta/epsilon) inhibitor	Phase 3	https://conductscience.org/library/genes/5422	Drugs and targets
POLA2	DNA polymerase (alpha/delta/epsilon)	2	DNA polymerase (alpha/delta/epsilon) inhibitor	Phase 3	https://conductscience.org/library/genes/23649	Drugs and targets

1 to 10 of 103

See all 103 targets

Trials5

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT02999633	Safety and Efficacy of Isatuximab in Lymphoblastic Leukemia	Phase 2	14	2020-01-18	T-cell Type Acute Leukemia-Precursor, T-lymphoblastic Lymphoma/Leukaemia	ISATUXIMAB	Its record names the disease	ClinicalTrials.gov
NCT00327678	Treatment of Acute Lymphoblastic Leukemia (ALL) in Younger Adults	Phase 3	1,080		Leukemia, Lymphocytic	IMATINIB MESYLATE, RITUXIMAB	Its record names the disease	ClinicalTrials.gov
NCT03117751	Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma	Phase 2/3	790		Acute Lymphoblastic Leukemia, Acute Lymphoblastic Lymphoma	BLINATUMOMAB, BORTEZOMIB, CALASPARGASE PEGOL, CLOFARABINE, CRISANTASPASE, CYCLOPHOSPHAMIDE, CYTARABINE, DASATINIB ANHYDROUS, DAUNORUBICIN, DEXAMETHASONE, DOXORUBICIN, ETOPOSIDE, IDARUBICIN, MERCAPTOPURINE, METHOTREXATE, NELARABINE, PEGASPARGASE, PREDNISONE, RUXOLITINIB, VINCRISTINE, VORINOSTAT	Its record names the disease	ClinicalTrials.gov
NCT07541755	PD-1 Inhibitors +Venetoclax+CAG Regimens in R/R T-ALL	Phase 3	40		Acute T Lymphoblastic Leukemia (T-ALL)	ACLARUBICIN, CYTARABINE, OMACETAXINE MEPESUCCINATE, VENETOCLAX	Open Targets' reading of its record	ClinicalTrials.gov
NCT07021677	Use of a New Medicine "Daratumumab" to Treat Left-over Cancer in a Blood Cancer Called "T Acute Lymphoblastic Leukemia"	Phase 2	18		T Acute Lymphoblastic Leukemia	DARATUMUMAB	Its record names the disease	ClinicalTrials.gov

Comparisons in its trials0

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

None in this release.

Papers from its trials50

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
35021604	RESULT	1	PubMed
34824885	RESULT	1	PubMed
34151693	RESULT	1	PubMed
33635331	RESULT	1	PubMed
33588922	RESULT	1	PubMed
33026700	RESULT	1	PubMed
32970151	RESULT	1	PubMed
32686081	RESULT	1	PubMed
32653327	RESULT	1	PubMed
32619115	RESULT	1	PubMed

1 to 10 of 50

See all 50 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0003539

GET https://conductscience.org/api/diseases/v1/MONDO_0003539/drugs?page=2

API reference For AI assistants